Risk Management Tools & Resources

 


Artificial Intelligence and Informed Consent

Laura M. Cascella, MA, CPHRM

Artificial Intelligence and Informed Consent

In healthcare, the basic concept of informed consent seems fairly straightforward. A patient is informed about a proposed test, treatment, or procedure; its benefits and risks; and any alternative options. With this knowledge, the patient decides to either consent or not consent to the recommended plan. In reality, though, informed consent is a more complex process that involves nondelegable duties and varies in scope based on the type of test, treatment, or procedure involved.

When technology is introduced into the mix — particularly advanced technology — the informed consent process can become even more complicated because of additional information that the provider must convey to the patient and that the patient must weigh as part of the decision-making process.

As artificial intelligence (AI) advances into healthcare with applications such as machine learning, deep learning, neural networks, and natural language processing, new ethical and practical issues related to informed consent are emerging. When should providers tell patients that they are using AI technologies for diagnostic and treatment purposes? How much information about the technology should they disclose? What are the best ways to explain the complexities of AI in understandable ways?

AI’s rapid momentum has, in many cases, eclipsed the ability of regulators, leaders, and experts to implement laws, standards, guidelines, and best practices that address some of these issues. An article in the Georgetown Law Journal notes that “This is not unusual when a new technology emerges—we struggle with whether it can be assimilated into existing doctrines or whether it requires something new.”1 As a result of this uncertainty, healthcare providers should stay vigilant for ongoing developments related to their legal and ethical responsibilities for disclosing information about AI during informed consent discussions.

Healthcare providers also must contend with how the media and popular culture might shape their views and their patients’ views of AI. An article in the AMA Journal of Ethics notes that “When an AI device is used, the presentation of information can be complicated by possible patient and physician fears, overconfidence, or confusion.” An example that might foreshadow this potential issue occurred with the emergence of robotic surgery. Vigorous direct-to-consumer advertising and marketing was noted in some instances to overestimate benefits, overpromise results, and/or fail to define specific risks, which led to inflated patient perceptions or unrealistic expectations of the technology.2

It is not difficult to see how media might also shape AI’s image, with persistent stories about how AI technologies will affect daily life in either fantastic or catastrophic ways. In a media-obsessed society, this inundation of information can have a significant impact on patients’ perceptions, potentially leading to idealistic or pessimistic views of AI. In turn, the need for thorough and appropriate informed consent discussions becomes even more pertinent.

To address issues related to patient knowledge and expectations of AI, healthcare providers must start with self-awareness and education about the technology. The authors of the aforementioned article explain that “for an informed consent process to proceed appropriately, it requires physicians to be sufficiently knowledgeable to explain to patients how an AI device works.”3 Although acquiring extensive knowledge of AI coding, programming, and functioning is likely unrealistic for most healthcare providers, those who plan to use these technologies in practice should be able to:

  • Provide patients with a general explanation of how the AI program or system works
  • Explain the healthcare provider’s experience using the AI program or system
  • Describe to patients the risks versus potential benefits of the AI technology (e.g., compared to human accuracy)
  • Discuss with patients the human versus machine roles and responsibilities in diagnosis, treatment, and procedures
  • Describe any safeguards that have been put in place, such as cross-checking results between clinicians and AI programs
  • Explain issues related to confidentiality of patient’s information and any data privacy risks

Taking the time to provide patients with these additional details during the informed consent process and to answer any questions can help ensure that they have the appropriate information to make informed decisions about their treatment. Following the informed consent process, providers should document these discussions in patients’ health records and include copies of any related consent forms.

In time, healthcare organizations and providers can use their experiences with AI, lessons learned during the implementation of AI in clinical care, and evolving federal and state regulations and professional standards to determine appropriate patient selection criteria for various AI applications and to hone informed consent processes.

For more information about informed consent, see MedPro’s guideline Risk Management Strategies for Informed Consent. To learn more about managing AI risks, see Risk Tips: Artificial Intelligence.

 


1 Cohen, G. (2020). Informed consent and medical artificial intelligence: What to tell the patient? Georgetown Law Journal, 108(6), 1,425–1,469. Retrieved from www.law.georgetown.edu/georgetown-law-journal/in-print/volume-108/volume-108-issue-6-june-2020/informed-consent-and-medical-artificial-intelligence-what-to-tell-the-patient/

2 Langreth, R. (2013, October 8). Robot surgery damaging patients rises with marketing. Bloomberg News. Retrieved from https://www.bloomberg.com/news/articles/2013-10-08/robot-surgery-damaging-patients-rises-with-marketing

3 Schiff, D., & Borenstein, J. (2019, February). How should clinicians communicate with patients about the roles of artificially intelligent team members? AMA Journal of Ethics, 21(2), E119-197. doi: 10.1001/amajethics.2019.138

MedPro Twitter

 

View more on Twitter